Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16589289 | 0.84 | FFAR1 (0.47) | MAOAMAOBFFAR1MAPTPOLB | |
| SCHEMBL15583974 | 0.80 | MAOB (0.61) | MAOAMAOBFFAR1PPARG | |
| SCHEMBL16636667 | 0.77 | GRIN2A (0.53) | FFAR1MAPTPOLBSMN1; SMN2TP53 | |
| SCHEMBL16592159 | 0.73 | MAOB (0.48) | MAOAMAOBFFAR1PPARG | |
| SCHEMBL16592128 | 0.72 | MAOB (0.47) | MAOAMAOBFFAR1PPARG | |
| SCHEMBL13711111 | 0.71 | BACE1 (0.62) | MAOAMAOB | |
| SCHEMBL4512841 | 0.69 | BACE1 (0.72) | FFAR1MAPTPOLBSMN1; SMN2 | |
| SCHEMBL16589296 | 0.69 | MAOB (0.49) | MAOAMAOBFFAR1PPARGGRM5 | |
| SCHEMBL15258130 | 0.69 | GRM3 (0.70) | — | |
| SCHEMBL11173291 | 0.67 | MRGPRX4 (0.63) | PPARGGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434695-B2 | Nitrogenous heterocyclic derivatives and their application in drugs | SUNSHINE LAKE PHARMA CO., LTD (CN) | 2016-09-06 | — | — | US | disclosed |
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150087639-A1 | Nitrogenous Heterocyclic Derivatives And Their Application In Drugs | TNNC1, TNNI3, IAPP | MAOA 119/4885MAOB 383/4885FFAR1 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.